General Oncology Care in Morocco

Abstract

Abstract The current population of Morocco is estimated to be 37 million based on the projection of the United Nations data. The median age in the Moroccan population is young. Around 25% of the population is aged under 14 years. Morocco is currently in an epidemiological transition called “double burden,” with the coexistence of infectious and chronic diseases. The most frequent cancers in men are lung, prostate, bladder, colorectum, and lymphoma. Whereas, for women, the most frequent are breast, cervix, colorectum, thyroid, and ovary. The first Moroccan cancer plan (2010–2019) has given the priority to breast and cervix cancers. Concerning treatments, the classical chemotherapies, hormonal therapies, and the first generation of monoclonal antibodies (Trastuzumab, Rituximab, Bevacizumab, Cetuximab, etc.,) are widely available for the entire population. Two immunotherapies are available in Morocco: Pembrolizumab and Atezolizumab. However, their reimbursement is still conflictual. 3D and new irradiation techniques are available in the major cities. Advanced minimally invasive techniques are now routinely performed for colorectal, liver, gynecologic, thoracic, and urologic cancers. The first surgical robot was acquired by the university hospital in Fez in 2019.